EMJ

EMJ #1 open access destination for HCPs & Pharma globally. Peer-reviewed journals & diverse content hub. Interviews, podcasts, webinars, infographics.

EMJ is the number one open access destination for HCPs and Pharma professionals globally. We do this across 18 therapy areas and the pharmaceutical sector via EMJ GOLD. We use industry-leading digital tools, to meet the challenges of time-poor medical professionals with a real passion to learn and in turn to elevate the quality of healthcare globally. Our content builds trust between healthcare professionals and Pharma, to help them continuously improve together. At the core of our content hub is a portfolio of peer reviewed, open access journals, which are complemented by alternative formats such as interviews, podcasts, webinars, and infographics. We have built our incredible team by recruiting on values. We stay true to these values in everything we do, as we remain steadfast in our goal to create Gold Medal Winners. For trusted partners who share our vision, we invite you to get in touch and join us on our journey.

Early ICU urine output patterns reveal hidden risk.Dynamic changes in urine output were strongly linked to death and AKI...
31/01/2026

Early ICU urine output patterns reveal hidden risk.

Dynamic changes in urine output were strongly linked to death and AKI in women with genitourinary infections.

đź”—

Early urine output trajectories predict mortality and acute kidney injury in female ICU patients with genitourinary infections. Read more to learn why.

Prospective European data offer cautious reassurance on pregnancy outcomes in women with severe sickle cell disease expo...
31/01/2026

Prospective European data offer cautious reassurance on pregnancy outcomes in women with severe sickle cell disease exposed to hydroxyurea.

Explore the data:

Large European cohort data suggest hydroxyurea pregnancy exposure in sickle cell disease is not linked to congenital malformations, supporting nuanced clinical decision-making.

Progress in hard-to-treat depression:Long-term follow-up shows sustained benefit from vagus nerve stimulation in patient...
31/01/2026

Progress in hard-to-treat depression:

Long-term follow-up shows sustained benefit from vagus nerve stimulation in patients with highly treatment-resistant major depression.

đź”—

Find out how vagus nerve stimulation delivers durable symptom relief and quality of life gains in treatment resistant depression patients.

30/01/2026

What’s shaping the future of haemophilia care in Europe?

In this episode of Hema Now, Catherine Glass speaks with senior leaders from the European Association for Haemophilia and Allied Disorders (EAHAD) to go behind the scenes of the EAHAD 2026 Congress.

They explore how the scientific programme is built, the vision guiding the meeting, and the key advances and challenges influencing haemophilia care across Europe.

🎧 Hear the full discussion: https://hubs.la/Q0410lJh0

Why are never-smokers becoming a larger part of the global lung cancer patient population?Find out now: https://hubs.la/...
30/01/2026

Why are never-smokers becoming a larger part of the global lung cancer patient population?

Find out now: https://hubs.la/Q040DnK-0

Have you seen our Flagship journal publication yet?Inside, uncover expert insights from our esteemed Editorial Board bel...
29/01/2026

Have you seen our Flagship journal publication yet?

Inside, uncover expert insights from our esteemed Editorial Board below:

- Dr Masood Nazir, NHS Birmingham & Solihull, UK
- Dr Rozelle Kane, University of Cambridge, UK
- Dr Nicholas Fuggle, University of Southampton, UK
- Dr Kinan Muhammed, Great Western Hospitals, NHS Foundation Trust, Swindon, UK

Read the journal free today here: https://hubs.la/Q040Tc8W0

29/01/2026

🎙️ NEW PODCAST SERIES: Regenerative Hepatology with Ludovic Vallier and host Catherine

Discover how stem cells and organoids are revolutionising liver disease treatment - from rapid-fire insights to deep dives on:

âś… Pluripotent stem cells and organoid integration
âś… Clinical translation vs. transplantation
âś… AI, small molecules and what's next in research

Listen now: https://hubs.la/Q040SWLf0

Did you know?People with psychiatric disorders face nearly double the risk of developing colorectal cancer compared to t...
29/01/2026

Did you know?

People with psychiatric disorders face nearly double the risk of developing colorectal cancer compared to those without psychiatric diagnoses.

Learn more: https://hubs.la/Q040Dqb50

28/01/2026

Don't miss out! Check out another highlight from our latest Flagship journal:

An inspiring interview with Michael Snyder, Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, who is a passionate advocate of healthy ageing.

Read now: https://hubs.la/Q040tbDN0

Cancer survival rates differ dramatically across the world, and now machine learning can help reveal why. By identifying...
28/01/2026

Cancer survival rates differ dramatically across the world, and now machine learning can help reveal why.

By identifying the key factors behind these disparities, this approach doesn't just explain the problem, but could guide health investment decisions in each country.

Uncover more: https://hubs.la/Q040DnyT0

27/01/2026

UK doctors are raising alarms about children's screen use.

NHS clinicians warn excessive screen time and harmful online content may be driving real physical and mental health harms in children, as under-16 social media restrictions are considered.

đź”— https://hubs.la/Q040w4Dl0

Address


Opening Hours

Monday 09:00 - 05:00
Tuesday 09:00 - 05:00
Wednesday 09:00 - 05:00
Thursday 09:00 - 05:00
Friday 09:00 - 05:00

Alerts

Be the first to know and let us send you an email when EMJ posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

EMJ is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics, alongside unique features and interviews.

The journal actively encourages members of the healthcare community to get involved, and there are plenty of opportunities to do so if you are interested. Featuring an online blog where both medical professionals, and members of the public can actively share their opinions about the most recent medical discoveries, debates, and controversies, EMJ welcomes contributions on relevant and topical subjects. For any members of the medical world who wish to act as editorial board members, peer-review papers, or even contribute articles to EMJ’s journals, then please do take a look at guidelines on the website: http://emjreviews.com/authors/, or get in contact to learn more: editor@emjreviews.com